It would be ideal to make the stable use of sodium-glucose cotransporter-2-inhibitors (SGLT-2is) at baseline a precondition for enrolment because SGLT-2is reduce kidney disease progression and mortality in patients with CKD, regardless of diabetes status.39 This evidence concerns the gene SLC5A2 and chronic kidney disease.